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Abstract
Background: Enhancer of zest homolog 2 (EZH2), a histone 3 methyltransferase, is associated with aggressive behavior
of many tumors and is a promising target of molecular therapy.
Methods: To better elucidate the relevance of EZH2 in breast cancer subtypes, we evaluated EZH2 expression in 226
invasive breast carcinomas with four distinct immunophenotypes and in association with clinicopathological features.
Results: Of these cases, 138 (61.1 %) were defined as EZH2-overexpressing with a multiplicative score > 3. EZH2
expression was inversely related to the status of ER and PR (Chi-square, p< 0.001), and it was significantly associated with
HER2 positivity, high proliferative index, and high histologic grade (Chi-square, p < 0.05). ER-positive breast carcinoma with
low proliferative index (Ki67 < 14 %) showed the lowest expression and triple-negative breast carcinoma showed the
highest overexpression of EZH2, 18.5 % (10/54) versus 90.9 % (50/55) (Chi-square, p < 0.001). Intriguingly, 88 % (44/50)
cases of grade 3 triple-negative breast carcinoma showed uniformly strong EZH2 expression with a multiplicative score of
9. The percentage of EZH2 overexpression in ER-positive breast carcinoma with a high proliferative index or HER2-positive
cases were 61.2 and 74 %, respectively. Furthermore, EZH2 expression was significantly elevated in high-grade DCIS
compared to benign lesions (90 % versus 0, p < 0.001). However, there is no association between EZH2 expression and
the status of histone 3 lysine 27 trimethylation or other clinicopathologic features.
Conclusion: In summary, triple-negative breast carcinoma showed the highest overexpression of EZH2. EZH2
overexpression is associated aggressive pathologic features including high nuclear grade, high proliferative index,
and positivity of HER2 of breast carcinoma.
Keywords: EZH2 overexpression, Immunophenotype, Triple-negative breast carcinoma, Proliferative index,
High nuclear grade
Background
Breast carcinoma comprises an extraordinarily diverse
group of diseases in terms of histology and clinical be-
havior and can be classified according to immunopheno-
typic features. ER-positive breast carcinoma is defined as
≥1 % of tumor cells being positive for ER, and usually
these are also positive for PR [1]. HER2-positive carcin-
oma shows either protein overexpression detected by
IHC or HER2 gene amplification by FISH [2]. Triple-
negative breast carcinoma is defined as combined negativ-
ity for ER, PR and HER2, which constitutes about 20 % of
breast cancer. Triple-negative carcinoma has attracted
much interest as an aggressive group that does not benefit
from the currently available anti-endocrine and anti-
HER2 treatment [3–5]. It is necessary to identify a bio-
marker for treating this unique breast carcinoma [6, 7].
High expression of Enhancer zest homolog 2 (EZH2), a
histone 3 methyltransferase, is related to unfavorable out-
come to tamoxifen in metastatic breast cancer and is an
independent predictor of survival in women with breast
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cancer [8, 9]. There are studies suggesting that EZH2
probably plays an important role in carcinogenesis of
breast carcinoma [10–18], and high expression of EZH2
was associated with triple-negative breast carcinoma
[15, 16, 18–21]. However, the association of EZH2 ex-
pression with clinicopathologic features such as PR,
HER2 expression, nuclear grade, and proliferative index
are inconsistent [8, 9, 22]. Reijm et al. reported that
there was no significant association between EZH2 pro-
tein expression and menopausal status, tumor hist-
ology, PR status [8]. they found a significant positive
association with the amount of lymph nodes involved,
histologic grade and HER2 status instead [8]. Whereas,
Bachmann et al. only reported high EZH2 expression was
associated with high histologic grade, locally advanced
cancers, and presence of distant metastatic disease of
breast carcinoma [9]. However, Kleer et al. demonstrated
that higher EZH2 levels were significantly associated with
negative ER status, negative PR status, but not HER2 over-
expression [22]. Furthermore, there is no reports concern-
ing EZH2 expression in different immunohistochemical
subgroups of breast carcinoma. So, in this study, EZH2 ex-
pression in 226 invasive breast carcinomas was assessed
by IHC, and the association with clinicopathologic fea-
tures was analyzed in Chinese cohort. We found that
triple-negative breast carcinoma showed the highest per-
centage of EZH2 overexpression compared to ER-positive
or HER2-positive subtypes, and 88 % (44/50) cases of
grade 3 triple-negative breast carcinoma showed uni-
formly strong EZH2 expression with a multiplicative score
of 9. Our study suggests that EZH2 overexpression is an
immunophenotypic feature of high-grade and highly pro-
liferative triple-negative breast carcinoma and is independ-
ently associated with a high proliferative index and HER2
positivity. Therefore, therapy targeting EZH2 should po-




Two hundred twenty-six invasive breast carcinomas di-
agnosed between January 1998 and December 2014 were
chosen from the archive at department of pathology in
Xi Jing Hospital. The cases were reviewed by breast pa-
thologists (S.P.G. and X.L.) and classified based on the
World Health Organization criteria for breast carcinoma
classification. The clinicopathologic information includ-
ing patient age, menstrual status, tumor size, tumor
stage, and lymph node stages were collected. The TNM
staging was determined by the 7th AJCC TNM staging
system. The histologic grade of invasive breast carcinoma
was graded according to the WHO criteria of breast car-
cinoma classification. 20 benign breast lesions comprising
of adenosis and usual ductal hyperplasia (UDH), 20 DCIS
adjacent to high grade triple-negative carcinoma and 20
DCIS adjacent to low to moderate grade non-triple-
negative carcinoma were also assessed for EZH2. This
study was approved by the institution review board of Xi
Jing Hospital.
Immunohistochemical staining and interpretation
The tissue was fixed in 10 % buffered formalin and proc-
essed as usual for paraffin embedding. Representative tissue
blocks of invasive breast carcinoma were selected by exam-
ination of the corresponding hematoxylin & eosin (HE)
stained slides and 5 μm thick sections were stained with
rabbit anti-human EZH2 antibody. Immunohistochemical
staining was performed using the Bond-Max automated
immunostainer (Vision Biosystems, Lecia, Autralia), with a
polymer-based detection system. EZH2 staining results
was interpreted independently by two breast patholo-
gists (S.P.G. and X.L.). Expression was assessed using a
multiplicative score of intensity and percentage of cells
stained for EZH2, where intensity (0 = no staining, 1 =
weak, 2 = moderate and 3 = strong) and percentage (1 =
<10 %, 2 = 11–50 %, and 3 = >50 %) were graded ac-
cording to the method described previously [8, 9]. A
multiplicative value of >3 was considered EZH2 overex-
pression and the maximum score of 9 was considered
strong overexpression. Immunostaining data for estro-
gen receptor (ER), progesterone receptor (PR), human
epidermal growth factor receptor 2 (HER2), Ki67, CK5/
6, and CK14 were collected from the archive. ER, PR,
HER2 were scored according to the ASCO/CAP guide-
line [1, 2]. The antibodies are shown in Table 1.
Fluorescence in-situ hybridization
Thirty cases expressing a HER2 protein score of 2+ by
IHC were assessed for the presence of HER2 amplification
on 4 μm FFPE sections using a standard probe (Abbott
Molecular, Des Plaines, IL). Cases were regarded as HER2
amplified if the HER2/CEP17 ratio was ≥2.0 or the average
HER2 copy number ≥ 6.0 signals/cell [2].
Statistical analysis methods
The associations between EZH2 expression and clinico-
pathologic features of the patients with breast carcinoma
were analyzed using Pearson’s chi-square test. Statistical
significance was defined as p < 0.05. Data were analyzed
using the Statistical Package for the Social Science Ver-
sion 17.0 (SPSS 17.0).
Results
The clinicopathologic features of breast carcinoma
All 226 patients were female with a median age of 47
(range 30–87) years who presented with breast masses.
Mastectomy, or breast conserving surgery with negative
margins and axillary lymph nodes excision were performed
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in all patients. Out of 226 cases, 26 were well differentiated
invasive carcinoma of nuclear grade 1, 86 were nuclear
grade 2, and the remaining 114 were poorly differentiated
carcinoma of nuclear grade 3. All cases were invasive car-
cinoma, not otherwise specific, except ten tubular carcin-
omas, five mucinous carcinomas which were included in
the group of nuclear grade 1. Immunostaining data for ER,
PR, HER2 were collected from the archive. 121 cases were
ER positive, and 105 cases were negative. 110 cases were
PR positive, and 116 cases were PR negative. Out of thirty
cases expressing a HER2 protein score of 2+ by IHC, only
nine cases showed the presence of HER2 gene amplifica-
tion. 50 cases were positive for HER2 protein or showed
HER2 gene amplification, 176 cases were negative for
HER2 according to the results of IHC and/or FISH in total.
Furthermore, the tumor were classified into three groups
according to tumor proliferation index Ki67 (<14 %, 14 %–
30 %, >30 %), and the case number was 74, 73 and 79 in
each group, respectively. The clinicopathologic information
of the cases was summarized in Table 2.
The association between EZH2 expression and
clinicopathologic characteristics of breast carcinoma
Of 226 cases of breast carcinoma, 209 cases of breast
carcinoma showed nuclear immunostaining of EZH2
with variable intensity and quantity. Low grade tubular
carcinoma with well formed tubules and mild nuclear
atypia (Fig. 1a) showed a low level of EZH2 expression
with only scattered positive cells (Fig. 1d). Invasive car-
cinoma, not otherwise specific type of nuclear grade 2
(Fig. 1b) showed moderate expression (Fig. 1e). Poorly
differentiated carcinoma of nuclear grade 3 with obvious
atypia and solid growth pattern (Fig. 1c) showed homo-
geneously strong expression of EZH2 (Fig. 1f ), while
seventeen low grade cases did not show any expression.
Of these cases, 61.1 % (138/226) were defined as EZH2-
overexpressing with a multiplicative score of intensity
and quantity > 3. Expression of EZH2 was inversely re-
lated to the statuses of ER and PR and significantly
higher (Chi-square, p < 0.001) in ER- and PR-negative
cases; the frequency of EZH2 overexpression in ER- and
PR-positive cases was 42.1 % (51/121) and 43.6 % (48/110),
versus 82.9 % (87/105) and 77.6 % (90/116) in ER- and PR-
negative cases respectively. Overexpression of EZH2 was
significantly higher in HER2-positive cases than HER2-
negative, 76 % (38/50) versus 56.8 % (100/176) (Chi-square,
p < 0.05). EZH2 overexpression was significantly associated
with the proliferative index, with 25.7 % (19/74), 68.5 %
(50/73), and 87.3 % (69/79) of breast carcinomas having
overexpression with a low (Ki67 < 14 %), moderate (Ki67
14 ~ 30 %) or high (Ki67 ≥ 30 %) proliferative index, re-
spectively (Chi-square, p < 0.001). The correlation between
EZH2 overexpression and nuclear grade was statistically
significant, with 38.5 % (10/26), 57 % (49/86), and 69.3 %
(79/114) of grade 1, 2, and 3 breast carcinomas having
overexpression of EZH2, respectively (Chi-square, p <
0.05). Intriguingly, none (0/15) of the specific-type low-
grade carcinomas (10 tubular carcinomas, five mucinous
carcinomas) had EZH2 overexpression. No statistically sig-
nificant difference was observed for other clinicopathologic
features including age, menstrual status, tumor stage (pT),
lymph node stage (pN) and expression of H3K27me3. The
association of EZH2 expression and clinicopathologic char-
acteristics of breast carcinoma is shown in Table 2. Single,
small clusters of carcinoma cells were obscured in the
stroma, and lobular cancerization was strongly evidenced
by nuclear expression of EZH2 in some cases.
EZH2 expression in different immunophenotype of breast
carcinoma
According to the statuses of ER, PR, HER2 and Ki67, all
breast carcinomas were classified into four subtypes: ER-
positive with a low proliferative index (Ki67 < 14 %), ER-
positive with a moderate to high proliferative index
(Ki67 ≥ 14 %), HER2 positive, and triple-negative. Of the
226 cases, 121 were classified as ER positive with at least
1 % positive tumor nuclei in the section. Of these, 54
cases were ER-positive with a low Ki67 index and 67
Table 1 The primary antibodies
Antibodies Clone Manufacturer Dilution
ER 6F11 Ventana, Tucson, AZ, USA Ready to use
PR AB-52 Santa Cruz Biotechnology, Dallas, Texas, USA 1:100
HER2 Polyclonal Sigma-Aldrich Shanghai Trading Co Ltd Shanghai, China Ready to use
Ki67 MIB-1 DAKO, Denmark Ready to use
CK5/6 D5/16B4 DAKO, Denmark 1:50
p63 4A4 Fuzhou Maixin, Biology, Fouzhou, China Ready to use
CK14 LL002 Fuzhou Maixin, Biology, Fouzhou, China Ready to use
EGFR Polyclonal Santa Cruz Biotechnology, Dallas, Texas, USA 1:100
EZH2 D2C9 Cell signaling Technology, Inc., Danvers, MA, USA 1:100
H3K27me3 C36B11 Cell Signaling Technology, Inc., Danvers, MA, USA 1:500
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cases were ER-positive with a moderate to high Ki67
index. Fifty cases were regarded as HER2-positive either
by demonstrating overexpression of the HER2 protein
using IHC or HER2 gene amplification by FISH. The
remaining fifty-five cases did not express either ER or PR
nor showed overexpression of the HER2 protein or HER2
gene amplification; these were classified as triple-negative.
ER-positive breast carcinoma with a low proliferative index
showed the lowest percentage of EZH2 overexpression,
whereas triple-negative breast carcinoma showed the high-
est percentage of EZH2 overexpression, 18.5 % (10/54)
versus 90.9 % (50/55), (Chi-square, p < 0.001). The percent-
age of EZH2 overexpression in ER-positive breast carcin-
omas with a moderate to high proliferative index and
HER2 positive groups were 61.2 % (41/67) and 74 % (37/
50) respectively. Intriguingly, EZH2 was uniformly strongly
overexpressed in 88 % (44/50) of triple-negative breast car-
cinomas with the maximum multiplicative score of 9. Rep-
resentative case of triple-negative breast carcinoma showed
typical histologic features such as high grade tumor cells ar-
ranged in cords and nests with prominent necrosis and
pushing border was shown in HE stained section (Fig. 2a).
The tumor cells were negative for HER2, ER, and PR
(Fig. 2b, c, d), and triple negative breast carcinoma usually
showed high tumor proliferative index Ki67 (Fig. 2e).
Strong overexpression of EZH2 with a score of 9 was ob-
served in high grade triple-negative breast carcinoma
(Fig. 2f).
The sensitivity and specificity of EZH2 overexpression
for detecting triple-negative was 51 and 86 % respect-
ively. EZH2 expression in ER-positive cases with moder-
ate to high proliferative index or HER2 positive breast
carcinoma was variable in both intensity and quantity,
and 51.2 % (21/41) and 51.4 % (19/37) showed strong
EZH2 overexpression with a maximum score of 9 in
these two cohorts respectively. No case of ER-positive
breast carcinoma with a low proliferative index showed
strong overexpression of EZH2 with a score of 9 (Table 3
and Fig. 3).
EZH2 overexpression in high-grade DCIS adjacent to
triple-negative breast carcinoma
EZH2 was mainly observed in the nuclei of epithelial
cells with variable intensity and quantity in breast tissue.
There was weak immunostaining of EZH2 in stromal fi-
broblasts, whereas the infiltrative germinal center B cells
of lymphoid follicles showed homogeneously strong
positivity. The expression of EZH2 in 20 benign breast
lesions comprising of adenosis and usual ductal hyper-
plasia (UDH) was also assessed. Compared with normal
or benign hyperplastic lobules and ducts, EZH2 expres-
sion was elevated in high-grade DCIS adjacent to triple-
negative breast carcinoma (0 versus 90 %, p < 0.001)
(Table 4). Breast lobules and UDH (Fig. 4a, b) only
expressed EZH2 in a low level (Fig. 4d, e), whereas
EZH2 was strongly overexpressed in high-grade DCIS
(Fig. 4c, f ), associated with invasive triple-negative breast
Table 2 EZH2 expression in breast carcinoma and relationship
with clinicopathologic characteristics










<50 133 36.8 % (49/133) 63.2 % (84/133) p > 0.05
≥50 93 41.9 % (39/93) 58.1 % (54/93)
Menopausal status
Premenopausal 125 36 % (45/125) 64 % (80/125) p > 0.05




Positive 121 57.9 % (70/121) 42.1 % (51/121)




Positive 110 56.4 % (62/110) 43.6 % (48/110)
Negative 116 22.4 % (26/116) 77.6 % (90/116)
Her2 p < 0.05
Positive 50 24 % (12/50) 76 % (38/50)
Negative 176 43.2 % (76/176) 56.8 % (100/176)
Ki67 p < 0.001
<14 % 74 74.3 % (55/74) 25.7 % (19/74)
14–30 % 73 31.5 % (23/73) 68.5 % (50/73)
>30 % 79 12.7 % (10/79) 87.3 % (69/79)
T stage
T1 105 33.3 % (35/105) 66.7 % (70/105) p > 0.05
T2 108 42.6 % (46/108) 57.4 % (62/108)




N0 94 38.3 % (36/94) 61.7 (58/94)
N1 64 37.5 % (24/64) 62.5 % (40/64)
N2 39 41 % (16/39) 59 % (23/39)
N3 29 41.4 % (12/29) 58.6 % (17/29)
Nuclear grade p < 0.05
1 26 61.5 % (16/26) 38.5 % (10/26)
2 86 43 % (37/86) 57 % (49/86)
3 114 30.7 % (35/114) 69.3 % (79/114)
H3K27me3 p > 0.5
Positive 220 39 % (86/220) 61 % (134/220)
Negative 6 33.3 % (2/6) 66.7 % (4/6)
Total 226 38.9 % (88/226) 61.1 % (138/226)
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carcinoma, and homogeneously strong positivity in 90 ~
100 % cells was observed; however, expression of EZH2
in low-grade DCIS was variable, with 55 % cases show-
ing overexpression. The intensity and quantity of EZH2
expression in DCIS was identical to those of correspond-
ing invasive components of the same case on the same
biopsy.
Discussion
Breast carcinomas are extraordinarily heterogeneous with
different clinicopathologic features and outcomes. The
statuses of ER, PR and HER2 are important for treatment
and prognosis. ER positive and HER2 positive breast car-
cinoma can benefit from anti-endocrine and anti-HER2
therapy, respectively. However, triple-negative carcinoma
shows aggressive behavior but do not benefit from current
available anti-endocrine or anti-HER2 targeted molecular
therapy [3–5]. Triple-negative breast carcinoma is defined
by immunophenotypic negativity for ER, PR and HER2
[3–5]. Without a targeted molecular therapy, triple-
negative breast cancer will continue to be threatening,
thus identifying potential targets will inform efforts to
combat this aggressive disease.
In the present study, we found that EZH2 was signifi-
cantly overexpressed in triple- negative breast carcinoma
and was associated with high tumor cell proliferation,
whereas low grade ER-positive breast carcinoma such as
tubular carcinoma and mucinous carcinoma showed low
EZH2 expression levels. A significant association be-
tween EZH2 overexpression with features of aggressive
breast carcinoma including high nuclear grade and
HER2 positivity was also found.
EZH2 expression was previously evaluated in breast
carcinomas and was reported to be significantly associ-
ated with increased tumor cell proliferation and as a
marker of aggressive behavior [21, 22]. The prognosis of
EZH2-positive breast carcinoma is worse than that of
EZH2-negative cases, as the 5-year survival rate was 81
and 91 % in patients with EZH2-positive or -negative
breast carcinoma, respectively [21]. As overexpression of
EZH2 in immortalized human mammary epithelial cell
lines promotes anchorage-independent growth and cell
Fig. 1 Immunostaining of EZH2 in invasive breast carcinoma of different nuclear grade with variable intensity and quantity were shown. Low grade
tubular carcinoma showed bland morphology with well formed tubules and mild atypia (a). A low level of EZH2 expression with only scattered positive
cells was observed in tubular carcinoma (d). Invasive carcinoma, not otherwise specific type of nuclear grade 2 (b) with moderate atypia showed moderate
expression of EZH2 (e). Poorly differentiated carcinoma of nuclear grade 3 was characterized with obvious atypia and solid growth pattern (c).
Homogeneously strong expression of EZH2 was detected in poorly differentiated carcinoma (f). (Magnification × 100)
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invasion, it is possible that EZH2 is involved in tumorigen-
esis of breast carcinoma [22]. We found that EZH2 is sig-
nificantly overexpressed in high-grade triple-negative
breast carcinoma: 90.9 % (50/55) of triple-negative breast
carcinoma showed overexpression of EZH2 with a multi-
plicative score of intensity and percentage >3, and 88 %
(44/50) among them showed homogeneously strong over-
expression in 90 ~ 100 % tumor cells with a multiplicative
score of 9 (Table 2). Conversely, ER-positive low grade
breast carcinoma with low proliferation (Ki67 < 14 %)
showed the lowest level expression of EZH2, with only
18.5 % (10/54) overexpressing EZH2; no case in this group
showed diffuse strong overexpression (Table 3).
We found that EZH2 expression in breast carcinoma
was significantly associated with tumor cell proliferation:
87.3 % (69/79) of breast carcinoma with high Ki67 index
(>30 %) showed high EZH2 levels, whereas only 25.7 %
(19/74) invasive breast carcinoma with a low Ki67 index
(<14 %) showed EZH2 overexpression. As EZH2 also
regulates cell cycle in addition to its histone H3 methyl-
transferase function [23], and EZH2 overexpression con-
tributes to uncontrolled mammary cell proliferation [24],
Fig. 3 EZH2 overexpressed in breast carcinoma and association with
immunophenotype. Triple- negative breast carcinoma showed the
highest percentage of EZH2 overexpression: 90.9 % (50/55) were
defined as EZH2 overexpression with a multiplicative score of intensity
and percentage > 3, and 88 % (44/50) among them showed strong
overexpression of EZH2 with a maximum multiplicative score of 9.
Low-grade ER-positive cases with low Ki67 index (<14 %) showed
the lowest percentage of EZH2 overexpression, with only 18.5 %
(10/54) having a multiplicative score >3, and no case garnered a
maximum multiplicative score
Fig. 2 Triple-negative breast carcinoma showed diffusely strong positivity for EZH2. Typical histologic features such as high grade tumor cells
arranged in cords and nest with prominent necrosis and pushing border were shown in HE stained section (a, Magnification × 100). The tumor
cells were negative for HER2, ER, and PR (b, c, d, Magnification × 400), and showed high tumor proliferative index Ki67 (e, Magnification × 100).
Strong overexpression of EZH2 was observed in high grade triple-negative breast carcinoma (f, Magnification × 400)
Table 3 Expression of EZH2 in subtype of breast carcinoma
Clinicopathologic features EZH2 score







54 18.5 % (10/54) 0 % (0/10) p < 0.001
ER positive with
high Ki67
67 61.2 % (41/67) 51.2 % (21/41)
Her2 positive 50 74 % (37/50) 51.4 % (19/37)
Triple-negative 55 90.9 % (50/55) 88 % (44/50)
Total 226 61.1 % (138/226) 62.3 % (86/138)
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the significant association between EZH2 overexpression
and Ki67 proliferative index further provides evidence of
EZH2 in the regulation of breast tumor cell prolifera-
tion. The association between expression of EZH2 and
HER2 is controversial in literature [9, 22]. We also found
that EZH2 overexpression was significantly high in
HER2 positive breast carcinoma by IHC or FISH com-
paring with negative cases, 76 % (38/50) versus 56.8 %
(100/176), p < 0.05. The significant association between
EZH2 overexpression and HER2 also supports a role of
EZH2 in regulation of tumor cell proliferation.
Recently, it was reported that BCL11A is a novel triple-
negative breast carcinoma oncogene, which was expressed
in 66.7 % (16/24) of triple-negative breast carcinomas
[25]. We did not evaluate BCL11A expression in our
226-case panel. Still, a direct comparison between
BCL11A and EZH2 in a large cohort is necessary to de-
cide if one better prognosticates. Further, we show that
EZH2 overexpression tracks with independently veri-
fied immunohistologic identification in our 226-case
study on breast carcinoma, particularly identifying es-
sentially all triple-negative cases and a large proportion
of high-grade HER2-positive cases. Consistent with pre-
vious studies [26, 27], we observed that EZH2 expres-
sion in normal epithelial cells of the terminal ductal
lobular unit of the breast and cells of benign breast
lesions is low with a multiplicative score <3. This sug-
gests that low levels of EZH2 are necessary to regulate
normal mammary epithelial cell proliferation; however,
EZH2 overexpression in ER-negative MDA-MB-231
cells results in decreased BRCA1 and uncontrolled pro-
liferation which contributes to tumorigenesis of breast
carcinoma [24]. Intriguingly, we observed that EZH2
was strongly overexpressed in high-grade DCIS adja-
cent to triple-negative breast carcinoma, whereas UDH
in benign lesions did not overexpress EZH2. This sug-
gests that aberrant expression of EZH2 may occur in
the early stage of carcinogenesis. Previous studies revealed
that EZH2 was up-regulated in DCIS and even morpho-
logically normal breast epithelial cells from patients with
Table 4 Expression of EZH2 in benign lesions and associated
with invasive carcinoma
Pathologic feature EZH2 score
Total N ≤3 >3 p value
Adenosis 10 100 % (10/10) 0 p< 0.001




20 10 % (2/20) 90 % (18/20)
DCIS associated with
low to moderate grade
non-triple-negative
carcinoma
20 45 % (9/20) 55 % (11/20)
Fig. 4 Immunostaining of EZH2 in benign lesions and high grade DCIS associated with triple-negative invasive breast carcinoma. Breast lobules,
and UDH which showed benign proliferation of epithelial and myoepithelial cells without any atypia were shown (a and b). Breast lobules, and
UDH expressed EZH2 in a low level, and only occasional EZH2 positive cells were observed (d and e). Representative high-grade DCIS associated
with invasive triple-negative breast carcinoma showed solid growth pattern and central necrosis (c) (Magnification × 100). EZH2 was strongly
overexpressed in high grade DCIS (f) (Magnification × 400)
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increased risk of breast carcinoma [26, 27], and EZH2
was reported as a molecular marker for identifying a
precancerous state in morphologically normal breast,
but these studies did not reveal the relationship of
EZH2 and triple-negative breast carcinoma and its in
situ components [26, 27]. Our finding of high overex-
pression of EZH2 in triple-negative DCIS as well as in-
vasive breast carcinoma supports an important role of
EZH2 in carcinogenesis of triple-negative breast carcin-
oma. Furthermore, the highest level of EZH2 expres-
sion was observed in high nuclear grade triple-negative
DCIS, which is consistent with the clinical evolution of
DCIS, as it is widely accepted that high nuclear grade
DCIS is associated with higher rate of recurrence than
low and intermediate nuclear grade DCIS. The finding
suggests that the high expression of EZH2 protein is asso-
ciated with breast carcinoma progresses. As we found that
EZH2 expression is unrelated to the status of H3K27me3
in the present study (Table 2), we argue it is likely that
EZH2 works in a histone methyltransferase-independent
manner in breast carcinoma pathogenesis. We think
EZH2 may further prove to be a useful marker for high-
grade triple-negative DCIS. Identification of high-grade
DCIS could be clinically meaningful and likely necessitates
close follow-up of these patients. Furthermore, as nuclear
staining of EZH2 can display single or small cluster of
tumor cells embedded in stroma, it is useful in detecting
micro-invasion of breast carcinoma in some cases.
The reason that epithelial cells lose ER and PR without
HER2 amplification during the process of malignant
transformation in triple-negative breast carcinoma, how-
ever, remains unclear. It is reported that EZH2 forms a
complex with NF-κB and activates transcription activity
of NF-κB in ER-negative MDA-MB-231 cells [24, 28]. As
this study demonstrates that EZH2 is consistently over-
expressed in high grade triple-negative breast carcinoma,
we hypothesize that EZH2 plays an important role in
tumorigenesis for this unique breast carcinoma.
Conclusion
In summary, our study demonstrates that EZH2 overex-
pression is significantly associated with high grade triple-
negative breast carcinoma as well as corresponding DCIS,
plus many high-grade HER2-positive breast carcinomas.
Because there was a strongly high association between the
Ki67 proliferation index and EZH2 expression levels, we
argue that EZH2 overexpression likely confers a prolifera-
tive advantage to EZH2-high cells which allows these
tumor cells to escape cell cycle regulation. Thus, inhibiting
EZH2 function may be relevant for treatment of triple-
negative breast carcinoma, which currently has no targeted,
effective therapy. Perhaps the next step is to assess the util-
ity of EZH2 inhibitors in EZH2-overexpressing triple-
negative breast carcinomas. EZH2 is a promising target for
prognostication and treatment in the aggressive and other-
wise unresponsive triple-negative breast carcinomas.
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